|Chemical and physical data|
|Molar mass||145.2 kg/mol g·mol−1|
Isatuximab is a monoclonal antibody (mAb) designed for the treatment of cancer. It was developed by ImmunoGen and Sanofi-Aventis with the development name SAR-650984. It was given orphan drug status for multiple myeloma by the FDA in December 2016.
Two additional phase III trials were launched in 2017. The first trial is assessing the benefit of isatuximab in combination with bortezomib, lenalidomide and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not eligible for transplant (IMROZ trial). The second trial is assessing the benefit of isatuximab combined with carfilzomib and dexamethasone versus carfilzomib with dexamethasone in patients with relapse and/or refractory multiple myeloma previously treated with 1 to 3 prior lines (IKEMA).
- Daratumumab, another anti-CD38 antibody
- Statement On A Nonproprietary Name Adopted By The USAN Council - Isatuximab, American Medical Association.
- ImmunoGen, Inc. Announces Data Presentations at Upcoming 57th ASH Annual Meeting and Exposition
- Martin, Th (2015). "A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma". Blood. 126 (23): 509.
- Clinical trial number NCT02999633 for "Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia" at ClinicalTrials.gov
- Clinical trial number NCT02990338 for "Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM)" at ClinicalTrials.gov
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|